Bremsstrahlung Imaging: A Valid Alternative For Dose Estimation In Patients Undergoing 90Y Zevalin Treatment

被引：0
|
作者：
Arrichiello, C. [1 ]
Mormile, M. [1 ]
D'Ambrosio, L. [1 ]
De Martinis, F. [1 ]
Squame, E. [1 ]
Frigeri, F. [1 ]
Arcamone, M. [1 ]
Aurilio, M. [1 ]
Aloj, L. [1 ]
Lastoria, S. [1 ]
机构：
[1] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2009年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S262 / S262
页数：1
相关论文
共 50 条
  • [21] How does the Internal Bremsstrahlung contribute to the Dose Point Kernel? The case of 90Y
    Auditore, L.
    Italiano, A.
    Pistone, D.
    Amato, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S61 - S61
  • [22] A phase ii study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL)
    Younes, A
    Rodriguez, M
    Pro, B
    McLaughlin, P
    Romaguera, J
    Hagemeister, F
    Wang, M
    ANNALS OF ONCOLOGY, 2005, 16 : 96 - 96
  • [23] A phase II study of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL).
    Oki, Y
    Pro, B
    Delpassand, E
    Ballaster, V
    McLaughlin, P
    Romaguera, J
    Wang, M
    Hagemeister, FB
    Younes, A
    BLOOD, 2004, 104 (11) : 720A - 720A
  • [24] Dose distribution parameters for the prescription in ICC (intrahepatic cholangiocarcinoma) patients undergoing Transarterial Radioembolization with 90Y
    Tarrats-Rosell, J.
    Cobo-Rodriguez, A.
    Ninerola-Baizan, A.
    Casanueva-Elicery, S.
    Romero-Zayas, I.
    Quintero, K.
    Fuster-Pelfort, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S809 - S810
  • [25] Energy Window Selection for Bremsstrahlung 90Y SPECT-CT Imaging: A Phantom Study
    Curto D.
    Bonutti F.
    Bouzekraoui Y.
    Bentayeb F.
    Asmi H.
    Iranian Journal of Medical Physics, 2022, 19 (01): : 43 - 48
  • [26] Measurement of Bremsstrahlung as a practical alternative to use of a liquid scintillation counter for the assessment of low activities of 90Y
    Sawyer, Laura J.
    Evans, Martyn J.
    Hiscock, Sarah C.
    NUCLEAR MEDICINE COMMUNICATIONS, 2007, 28 (08) : 631 - 636
  • [27] Incidence of altered biodistribution detected by indium 111 (111In) imaging prior to yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) radioimmunotherapy:: Results from a Zevalin imaging registry.
    Conti, P
    White, C
    Pieslor, P
    Menendez, G
    Harrough, VD
    Matso, D
    Aussie, J
    Ryskamp, T
    Foster, PA
    BLOOD, 2004, 104 (11) : 226B - 227B
  • [28] The nursing role in the successful implementation of a clinical treatment team for radioimmunotherapy with zevalin (90Y ibritumomab tiuxetan.
    Pellegrini, C
    Khandekar, S
    Shelley, M
    Tripp, B
    ONCOLOGY NURSING FORUM, 2004, 31 (02) : 399 - 400
  • [29] Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL).
    Younes, A
    Pro, B
    Rodriguez, MA
    Romaguera, JE
    McLaughlin, P
    Wang, M
    Hagemeister, FB
    Dang, NH
    Neelapu, S
    Podoloff, D
    BLOOD, 2005, 106 (11) : 689A - 690A
  • [30] Using an assumed lung mass underestimates the lung absorbed dose in patients undergoing 90Y radioembolization therapy
    Dodson, Cassidy
    Marshall, Colin
    Durieux, Jared
    Wojtylak, Patrick
    Tavri, Sidhartha
    Davidson, Jon
    Muzic, Raymond, Jr.
    Kardan, Arash
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
12345